Navigation Links
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Date:11/13/2008

with a corresponding negative predictive value of 99.1%. Patients with CIN2 are at risk of developing cervical cancer, however this risk is not as high as it is for those diagnosed with CIN3.

-- When compared to the ASC-US/LSIL Triage Study (ALTS), the Cervista HPV high-risk test has a comparable specificity to the test used in that study. The ALTS trial is the best comparative trial for the Cervista HPV high-risk trial based on similarities in trial design.

The Cervista HPV high-risk test has additional advantages including:

-- The Cervista HPV high-risk test has demonstrated a low indeterminate rate (i.e. inability of the test to give a result) of less than 1% and no cross reactivity with commonly reported low-risk HPV types.

-- An internal control that minimizes the potential for a false negative result due to insufficient sample cellularity.

-- Small volume of liquid-based cytology sample required for HPV testing. Hologic believes that this will reduce the percentage of "quantity not sufficient" samples that are burdensome to the lab, physicians and patients alike.

-- Workflow advantages for the laboratory. The Cervista HPV high-risk test requires minimal hands on time, and yields a rapid time to results.

In addition to the results for the Cervista HPV high-risk test, Hologic also announced today the clinical trial results for the Cervista 16/18 test, a genotyping test for high-risk HPV types 16 and 18, which are responsible for approximately 70% of all cervical cancers. The Cervista(R) 16/18 test is also pending FDA approval. Similar to the high risk screening test, the Cervista 16/18 test results were compared to CIN2 and CIN3 clinical end-points. Two potentially important findings were Negative Predictive Values for 99.5% for CIN3 and 97.7% for CIN2+. Recent consensus guidelines released by the American Society for Colposcopy and Cervical Pathology (ASCCP) in 2007 stated that "...it would be reasonable to util
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
2. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , 2. Juli 2015 BGI ... DNA-Screening in Hongkong vom American College of ... Hongkong ist das erste klinische Next-Generation-Sequencing Labor, ... ein CAP-Zertifkat erhält und somit die höchsten ... den bestehenden US FDA - 21 CFR ...
(Date:7/2/2015)... Wash. , July 2, 2015   BioLife Solutions ... and marketer of proprietary clinical grade cell and tissue ... a related cloud hosted biologistics cold chain management app ... today announced that Seattle Business Magazine has included ... to work for in Washington state ...
(Date:7/2/2015)... LONDON , July 2, 2015 ... commitment to improving access to HIV treatments   ... a strategic manufacturing agreement to enable production in ... additional source of the dolutegravir active pharmaceutical ingredient (API), and ... the finished product (dolutegravir 50mg, marketed under the name Tivicay®) ...
Breaking Medicine Technology:BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6
... GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, ... presented at,the 97th annual meeting of the ... support the use of adenovector systems,to deliver ... lead product candidate, TNFerade(TM) biologic (TNFerade),is an ...
... Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), ... targeted,medicines primarily for cancer treatment, today announced ... at the 98th Annual Meeting,of the American ... Curis also disclosed that its April 2005 ...
Cached Medicine Technology:GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 2GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Indiana ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/2/2015)... ... July 02, 2015 , ... After conducting a nationwide ... Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, as chief ... medical management, Dr. Trenschel will assume his new duties at Yuma Regional Medical Center ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report summarizes ... manufacturers. The report is a valuable source of guidance and direction for companies ... Chinese market for the Gelatin Capsule industry including capacity, production, production value, cost ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... ... ... DUI arrests and fatalities spike on the 4th of July. In fact, because of drunk ... comes to being on the road. According to attorney David J. Maloney , the ... highway deaths between 2007 and 2011 were caused by drunk driving over the 4th of ...
Breaking Medicine News(10 mins):Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2
... 2 in the morning helped adults lose 65% more weight, ... eggs may help overweight adults lose weight and feel more ... of overweight or obese adults, ages 25 to 60, found ... of a calorie-reduced diet lost 65 percent more weight, had ...
... cancer patients and their physicians may make more informed, ... determine probability of recurrence, a research team led by ... Cancer Center reported in the Aug. 12 online issue ... . , The 2,838 women studied were diagnosed with ...
... As more people send text messages, repetitive strain injury cases are on ... ... 12 SpinVox, the leader in voice-to-content,messaging, today issued new guidelines to ... of all ages texting furiously at all hours of the day, we,are ...
... person with a disability, MINNEAPOLIS, Aug. 12 ... for people with disabilities, is seeking,applications for its ... 1992, the Jacobson Award recognizes the pursuit or,achievement ... with a,physical disability or sensory impairment. The award ...
... New study fails to settle question about best treatment ... -- The latest update from a European study that ... a decade leaves the debate about the advantages of ... in survival seen for men who underwent surgery to ...
... The Quantum Group,Inc. (Amex: QGP ) ... today that Noel J. Guillama, President &,CEO, will ... Conference at,5:00 p.m. (Pacific) on Monday, August 18, ... Mr. Guillama will give a 23-minute presentation ...
Cached Medicine News:Health News:Risk assessment plays key role in long-term treatment of breast cancer 2Health News:SpinVox Offers New Guidelines to Prevent Repetitive Strain Injuries 2Health News:SpinVox Offers New Guidelines to Prevent Repetitive Strain Injuries 3Health News:Courage Center Seeks Applications for Judd Jacobson Memorial Award 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Designed for use in traditional external approach DCRs in pediatric patients & for endoscopic DCRs in adults or children. Lumen 6.0mm long, ID-1.4mm (.12 in); OD-5.0mm (.20 in), Outer flanges 8.0mm ...
Medicine Products: